Ikena Oncology, Inc. (IKNA) Dividend History

Ikena Oncology, Inc. is a biopharmaceutical company focused on developing targeted therapies for cancer. It utilizes its proprietary platform to identify and develop treatments aimed at genetic and molecular drivers of cancer, with a focus on precision medicine approaches to improve patient outcomes.

50 Northern Ave., Boston, MA, 02210
Phone: 857-343-8292
Website:

Dividend History

Ikena Oncology, Inc. currently does not pay dividends

Company News

  • Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

    Ikena Oncology and Inmagene Biopharmaceuticals have announced a merger agreement, with Inmagene's lead asset IMG-007, a non-depleting anti-OX40 monoclonal antibody, as the focus of the combined company. The transaction is expected to result in $175 million to support further development of IMG-007.

    Benzinga
  • Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It 'Disappointing'

    On Tuesday, Ikena Oncology Inc (NASDAQ:IKNA) discontinued the clinical IK-930 program, the company’s TEAD1- selective Hippo pathway inhibitor, and continued clinical development of IK-595, a novel MEK-RAF molecular glue. Concurrently, Ikena is evaluating strategic options for the company and its development pipeline. The company said that based on a review of clinical data to date, available resources, and strategic priorities, the company decided to discontinue the development of IK-930. The IK-930 Phase 1 program will begin winding down activities; treatment will continue for enrolled patients who have derived benefits. The company will seek strategic options for the program, including potential partners for developing IK-930 in combination with other targeted agents. In November 2023, Ikena shared initial data from twenty-six patients treated in ...Full story available on Benzinga.com

    Benzinga
  • This American Airlines Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Wedbush analyst David Nierengarten downgraded the rating for Ikena Oncology, Inc. (NASDAQ:IKNA) from Outperform to Neutral, while slashing the price target from $8 to $2. Ikena Oncology shares closed at $1.33 on Tuesday. See how other analysts view this stock. Wells Fargo analyst Finian O’Shea downgraded Goldman Sachs BDC, Inc. (NYSE:GSBD) from Equal-Weight to Underweight and cut the price target from $15 to $14. Goldman Sachs BDC shares ...Full story available on Benzinga.com

    Benzinga
    Featured Companies: AAL AAL GSBD OZK WCC
  • UPDATE – Ikena Oncology Announces Strategic Update

    Ikena to discontinue development of IK-930

    GlobeNewswire Inc.
  • Ikena Oncology Announces Strategic Update

    Ikena to discontinue development of IK-930

    GlobeNewswire Inc.
Dividend data last updated 06/08/2025 00:16:35 UTC